I-Genital Psoriasis: Iziphumo zeSifundo esitsha

A BAMBA isiKhululo sasimahla 1 | eTurboNews | eTN

U-Amgen namhlanje ubhengeze iziphumo ezilungileyo eziphezulu ezivela kulingo lwe-DISCREET, iSigaba se-3, i-multicenter, i-randomized, i-placebo-controlled, i-double blind-blind study ukuvavanya ukusebenza kwe-Otezla® (i-apremilast) kubantu abadala abane-moderate ukuya kwi-psoriasis ye-genital kunye ne-moderate to. i-psoriasis enzima kakhulu.

Uphononongo lubonise ukuba i-Otezla yomlomo i-30 mg kabini imihla ngemihla iphumelele uphuculo olunentsingiselo yeklinikhi kunye nezibalo, xa kuthelekiswa ne-placebo, kwinqanaba eliphambili le-static Physician's Global Assessment ye-Genitalia (sPGA-G) impendulo (echazwe njengenqaku le-sPGA-G). ecacileyo (0) okanye ephantse yacaca (1) ubuncinane ngamanqaku ama-2 ukusuka kwisiseko) ngeveki ye-16.      

Ukongezelela, zonke isiphelo sesibini zaye zadibana nokuphuculwa okunentsingiselo kunye nokubalulekayo kwi-Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) impendulo (echazwe ubuncinane i-4-point inciciation ukusuka kwisiseko kwi-GPI-NRS amanqaku amanqaku ngaphakathi kwe-Genital Psoriasis Symptoms. kwizifundo ezinamanqaku asisiseko ≥ 4); indawo yomzimba ochaphazelekayo (BSA) utshintsho ukusuka kwisiseko; I-Dermatology Life Quality Index (DLQI) utshintsho ukusuka kwisiseko; kunye ne-static Physician's Global Assessment (sPGA) impendulo (echazwe njenge-sPGA amanqaku acacileyo (0) okanye aphantse acace (1) kunye nokunciphisa amanqaku angama-2 ukusuka kwisiseko) ngeveki ye-16 kunye ne-Otezla ngokumelene ne-placebo.

Uhlobo kunye nezinga leziganeko ezimbi ezibonwe kolu vavanyo lwaluhambelana neprofayili eyaziwayo yokhuseleko lwe-Otezla. Iziganeko ezibi kakhulu ezichazwe ngokuqhelekileyo ezenzeke ubuncinane kwi-5% yezigulane kulo naliphi na iqela lonyango yayiyi-diarrhea, intloko ebuhlungu, isicaphucaphu kunye ne-nasopharyngitis.

Izigulane ezigqiba isigaba se-double-blind-blind of the trial yaqhubeka okanye itshintshelwe kwi-Otezla ngexesha lokwandiswa kwesigaba sophando kwaye iya kunyangwa ngeveki 32. Uphononongo luyaqhubeka kwaye lucetywa ukugqiba kwisiqingatha sokuqala se-2022.

Iziphumo ezicacileyo ezivela kwi-16-iveki ye-double blind-blind isigaba sophononongo iya kuhanjiswa ukuba iboniswe kwinkomfa yezonyango ezayo.

E-US, i-Otezla ivunyiwe kunyango lwabaguli abadala abane-plaque ephakathi ukuya kwi-psoriasis enzima abangabaviwa be-phototherapy okanye unyango lwenkqubo, abaguli abadala abane-psoriatic arthritis esebenzayo kunye nabaguli abadala abanezilonda zomlomo ezinxulumene ne-Behçet's Disease. Ukususela ekuvunyweni kwayo kokuqala kwe-FDA ngo-2014, i-Otezla iye yamiselwa ngaphezu kwezigulane ze-650,000 kwihlabathi jikelele ezine-plaque psoriasis ephakathi, i-psoriatic arthritis esebenzayo okanye i-Behçet's Disease.

Malunga nombhali

I-avatar kaLinda Hohnholz, umhleli we-eTN

U-Linda Hohnholz, umhleli we-eTN

U-Linda Hohnholz ubhale kwaye wahlela amanqaku ukusukela oko waqalisa ukusebenza. Usebenzise olu thando lwangaphakathi kwiindawo ezinje ngeHawaii Pacific University, iYunivesithi yaseChaminade, iZiko lokuFumanisa abantwana laseHawaii, kwaye ngoku iTravelNewsGroup.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...